BELITE BIO, INC
Clinical-stage biopharma developing therapies for retinal and metabolic diseases.
BLTE | US
Overview
Corporate Details
- ISIN(s):
- US07782B1044
- LEI:
- Country:
- United States of America
- Address:
- 12750 HIGH BLUFF DRIVE SUITE 475, 92130 SAN DIEGO
- Website:
- https://belitebio.com/
- Sector:
- Manufacturing
Description
Belite Bio is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for retinal degenerative eye diseases and metabolic conditions with significant unmet medical needs. The company's lead candidate, Tinlarebant (LBS-008), is a novel oral therapy designed to reduce the accumulation of ocular toxins by targeting Retinol Binding Protein 4 (RBP4). Tinlarebant is in late-stage clinical development for the treatment of Stargardt disease (STGD1) and Geographic Atrophy (GA), an advanced form of dry age-related macular degeneration. The drug has received multiple regulatory designations, including Orphan Drug, Rare Pediatric Disease, Breakthrough Therapy, and Fast Track in the U.S., as well as Orphan Drug designation in Europe and Sakigake designation in Japan.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all BELITE BIO, INC filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BELITE BIO, INC
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BELITE BIO, INC via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
